Halberd Corporation (OTC:HALB) President and CEO Bill Hartman and Chief Technology Officer Dr Mitchell Felder tell Proactive that the company has reached a significant milestone after its researchers demonstrated the ability to precisely control the level of PD-1 (programmed cell death–1) in human blood serum in laboratory in-vitro testing.
PD-1 is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the tumor to grow.
Felder explained that Halberd’s extracorporeal process, operating on blood serum, can potentially be used to eliminate PD-1 and allow the body’s innate immune system to attack and eliminate the cancer tumor.